Ostrovskaya L A, Blyukhterova N V, Fomina M M, Rykova V A, Korman D B, Burlakova E B
N. M. Emanuel' Institute of Biochemical Physics, Russian Academy of Sciences, Moscow.
Bull Exp Biol Med. 2003 Jan;135 Suppl 7:48-9. doi: 10.1023/a:1024766310424.
Antitumor activity of ultralow doses of cytostatic doxorubicin was studied on BDF1 mice with Lewis lung carcinoma. The preparation was injected intraperitoneally in single doses of 10(-5), 10(-10), 10(-15), and 10(-20) M on the next day after tumor inoculation. The effect of ultralow doses was compared with that of a standard therapeutic dose of doxorubicin (8 mg/kg, 1.4 x 10(-3) M). Doxorubicin in ultralow doses produced an antitumor effect comparable with that induced by the preparation in standard doses. On day 12 after administration of doxorubicin in ultralow and standard doses, tumor size in mice did not exceed 20% of the control level.
研究了超低剂量的细胞抑制性阿霉素对患有Lewis肺癌的BDF1小鼠的抗肿瘤活性。在肿瘤接种后的第二天，以10(-5)、10(-10)、10(-15)和10(-20)M的单剂量腹腔注射该制剂。将超低剂量的效果与阿霉素的标准治疗剂量（8mg/kg，1.4x10(-3)M）的效果进行比较。超低剂量的阿霉素产生的抗肿瘤效果与标准剂量制剂诱导的效果相当。在给予超低剂量和标准剂量阿霉素后的第12天，小鼠的肿瘤大小不超过对照水平的20%。
